Explorar vídeo

PEACE-1 clinical trial demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) and radiographic progression-free-survival (rPFS) in men with de novo mCSPC.

ASH 2022 - Update on Myelodysplastic Syndromes

Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.

Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.

EHA Updates AML : QuANTUM phase 3 study showed significant overall survival in adults having FLT3-ITD+ acute myeloid leukaemia with  addition of quizartinib to standard induction and consolidation therapy alone.

Integrating molecular prognostic systems into MDS clinical practice enhances risk stratification by combining genetic data with traditional scoring systems.

Over the last few years treatment of Nasopharyngeal Carcinoma has evolved with minimally invasive surgery, advances in chemotherapy & immunotherapy.

Learn about successful treatment of 72 year old Renal Cell Carcinoma Patient also suffering from Rheumatoid Arthritis treated with single agent TKI

I-SPY2 clinical trial laid the foundation for Immunotherapy in Early Breast Cancer with Pembrolizumab added to Neoadjuvant Chemotherapy.

There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.